NASDAQ:KRSA Cyclerion Therapeutics (KRSA) Stock Price, News & Analysis $32.68 +1.03 (+3.25%) Closing price 04:00 PM EasternExtended Trading$32.84 +0.16 (+0.49%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Cyclerion Therapeutics Stock (NASDAQ:KRSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cyclerion Therapeutics alerts:Sign Up Key Stats Today's Range$31.43▼$34.1850-Day Range$30.07▼$37.1952-Week Range$7.19▼$59.36Volume319,840 shsAverage Volume175,272 shsMarket Capitalization$1.49 billionP/E RatioN/ADividend YieldN/APrice Target$51.20Consensus RatingModerate Buy Company Overview Cyclerion Therapeutics was a clinical-stage biotechnology company focused on developing medicines for serious disorders of the central nervous system. The company originated as a spinout from Ironwood Pharmaceuticals in 2019 and was based in Cambridge, Massachusetts. Its research centered on small-molecule drugs that stimulate soluble guanylate cyclase, an enzyme involved in cellular signaling. Cyclerion’s development portfolio included zagociguat, an investigational, brain-penetrant candidate studied for conditions including cognitive impairment associated with Alzheimer’s disease and other neurological disorders. Cyclerion later pursued a strategic transaction with Tisento Therapeutics. Its programs and corporate status have since been subject to that transition, so the company’s historical drug-development activities may not reflect its current business.AI Generated. May Contain Errors. Read More Cyclerion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreKRSA MarketRank™: 3.885278514585 of 5 starsCyclerion Therapeutics scored higher than 78% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCyclerion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCyclerion Therapeutics has a consensus price target of $51.20, representing about 56.7% upside from its current price of $32.68.Amount of Analyst CoverageCyclerion Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cyclerion Therapeutics' stock forecast and price target. Earnings and Valuation0.7 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cyclerion Therapeutics are expected to grow in the coming year, from ($5.35) to ($3.58) per share.Price to Book Value per Share RatioCyclerion Therapeutics has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.53% of the float of Cyclerion Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclerion Therapeutics has a short interest ratio ("days to cover") of 0.94, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclerion Therapeutics has recently increased by 603.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCyclerion Therapeutics does not currently pay a dividend.Dividend GrowthCyclerion Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.93 News SentimentCyclerion Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cyclerion Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Cyclerion Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders31.04% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cyclerion Therapeutics' insider trading history. Receive KRSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRSA Stock News HeadlinesCyclerion Therapeutics (NASDAQ:KRSA) Stock Rated "Overweight" in New Coverage at Wells Fargo & CompanyNovember 16 at 1:15 AM | americanbankingnews.comKorsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 5, 2026 | globenewswire.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 16 at 1:00 AM | Profits Run (Ad)Korsana Biosciences to Participate in Upcoming Investor ConferencesNovember 2, 2026 | globenewswire.comKorsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 MillionSeptember 8, 2026 | globenewswire.comCyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s PipelineApril 21, 2026 | finance.yahoo.comPenny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?April 2, 2026 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)April 2, 2026 | prnewswire.comSee More Headlines KRSA Stock Analysis - Frequently Asked Questions How have KRSA shares performed this year? Cyclerion Therapeutics' stock was trading at $31.91 on September 11, 2026. Since then, KRSA shares have increased by 2.4% and is now trading at $32.68. How were Cyclerion Therapeutics' earnings last quarter? Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) issued its earnings results on Thursday, November, 5th. The company reported ($3.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($50.40) by $47.21. When did Cyclerion Therapeutics' stock split? Cyclerion Therapeutics shares reverse split before market open on Tuesday, May 16th 2023.The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Cyclerion Therapeutics? Shares of KRSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cyclerion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), NIO (NIO), Energy Transfer (ET), Carnival (CCL), OPKO Health (OPK) and Plug Power (PLUG). Company Calendar Last Earnings11/05/2026Today11/16/2026UBS Global Biopharma Conference 202611/16/2026Jefferies Global Healthcare Conference11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 KRSA's financial health is in the Green zone, according to TradeSmith. KRSA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:KRSA Previous SymbolNASDAQ:CYCN CIK1755237 Webwww.korsana.com Phone(617) 621-7722FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Cyclerion Therapeutics$51.20 High Price Target$70.00 Low Price Target$43.00 Potential Upside/Downside+56.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($12.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.53 million Net MarginsN/A Pretax Margin-3,064.29% Return on Equity-50.57% Return on Assets-42.79% Debt Debt-to-Equity RatioN/A Current Ratio10.42 Quick Ratio0.82 Sales & Book Value Annual Sales$2.07 million Price / Sales718.96 Cash FlowN/A Price / Cash FlowN/A Book Value$8.60 per share Price / Book3.80Miscellaneous Outstanding Shares45,540,000Free Float31,405,000Market Cap$1.49 billion OptionableN/A Beta1.85 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:KRSA) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman and Jensen Huang could one day be worth more than Ap...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.